MapLight Therapeutics names Martin Babler, Troy Cox to board of directors

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT

0.00
  • MapLight Therapeutics added Martin Babler and Troy Cox to its board following their election at the June 23 annual meeting.
  • Babler, CEO and chairman of Alumis since September 2021, joined the audit committee; he previously led Principia Biopharma.
  • Cox, former Foundation Medicine CEO (2017-2019), became chair of the nominating and corporate governance committee; he previously held senior roles at Genentech.
  • They replaced Robert Malenka and Jim Trenkle, who did not stand for re-election and have left the board.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240700PRIMZONEFULLFEED9751749) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.